Harder for T cells to fight cancer in absence of VEGF-A

Contrary to what was previously believed, the immune system’s cancer-killing T cells are more effective in a tumour’s anoxic environment when they have access to growth factor VEGF-A. In a study from Karolinska Institutet published in Cancer Cell, the researchers show how the T cells not only survive in this oxygen-depleted micro-environment with the help of transcription factor HIF-1a but also become more effective at killing cancer cells inside it.

Cytotoxic T cells are important for the immune system in their ability to kill tumour cells. When the T cells enter a tumour, they are thought to exploit transcription factor HIF, which like all transcription factors is a protein that regulates gene expression and thus the function of the cell. Transcription factor HIF is also especially able to help the T cells to adapt to the tumour’s anoxic micro-environment.

The researchers now show that it is the variant HIF-1a that enabled the T cells to adapt to this oxygen-depleted environment and thus succeed in killing the tumour. After having analysed the variant HIF-2a they found that it was less important than HIF-1a for the T cells’ ability to adapt to the lack of oxygen and fight the tumour.

“We observed that the T cells detect oxygen, and by adapting to a limited amount of oxygen they can enter anoxic tumours, survive within them and then effectively kill them,” says Professor Randall Johnson at Karolinska Institutet’s Department of Cell and Molecular Biology, who led the study.

Loss of growth factor resulted in larger tumours

The researchers also used mouse models to try to knock out VEGF-A (a growth factor that makes blood vessels grow and one of HIF’s target genes) from their T cells.

“Doing this, we found that the tumours grew and that the formation of new blood vessels changed,” explains Professor Johnson. “This is interesting because it was previously thought that tumours starve when you reduce VEGF-A. Our research shows that things are more complex than this. I hope that our discovery will lead to better tumour therapy that maximises the effect of the T cells.”

The study was financed by the Wellcome Trust Research Fellowship, the Swedish Cancer Society, the Swedish Childhood Cancer Foundation, the Swedish Research Council, the US National Institutes of Health and the Marie Curie IEF fellowship.

Text: Maja Lundbäck

Publication

“An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression”
Asis Palazon, Petros A. Tyrakis, David Macias, Pedro Velica, Helene Rundqvist, Susan Fitzpatrick, Nikola Vojnovic, Anthony T. Phan, Niklas Loman, Ingrid Hedenfalk, Thomas Hatschek, John Lövrot, Theodoros Foukakis, Amanda W. Goldrath, Jonas Bergh, Randall S. Johnson
Cancer Cell, 13 November 2017, doi: 10.1016/j.ccell.2017.10.003